NCT00732563 is a NA clinical trial of chemotherapy in Lung Cancer, sponsored by Roswell Park Cancer Institute.

Who is sponsoring NCT00732563?

NCT00732563 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT00732563?

Interventions in NCT00732563: chemotherapy, lymphadenectomy, neoadjuvant therapy, quality-of-life assessment, therapeutic conventional surgery, thoracic surgical procedure, fludeoxyglucose F 18, radiation therapy.

What condition does NCT00732563 study?

NCT00732563 studies Lung Cancer.

Is NCT00732563 still recruiting?

NCT00732563 is currently completed. Last updated 18 October 2017.

Last reviewed 2017-10-18 · How we verify

NCT00732563

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Completed NA Last updated 18 October 2017

What this trial tests

NA trial testing chemotherapy in Lung Cancer in 100 participants. Completed in 26 July 2017.

Timeline

16 July 2008

Primary endpoint
29 June 2012

26 July 2017

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	16 July 2008
Primary completion	29 June 2012
Estimated completion	26 July 2017
Sites	1 location across United States

Drugs / interventions tested

chemotherapy (chemotherapy) — full drug profile →
lymphadenectomy
neoadjuvant therapy — full drug profile →
quality-of-life assessment
therapeutic conventional surgery
thoracic surgical procedure
fludeoxyglucose F 18 — full drug profile →
radiation therapy — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Roswell Park Cancer Institute

Who can join

Adults 18 to 120, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Diagnostic procedures using fludeoxyglucose F 18 and a surgical probe may help find lymph node metastases in patients with early-stage non-small cell lung cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 works in detecting lymph node metastasis in patients with stage I or stage II non-small cell lung cancer that can be removed by surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of chemotherapy

Trials testing the same drug.

NCT07035392 — Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC · Phase 2 · not yet recruiting
NCT06599827 — Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC · Phase 2 · not yet recruiting
NCT07437898 — Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study · Phase 2 · recruiting
NCT06306560 — A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. · Phase 2 · not yet recruiting
NCT06121505 — Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced · Phase 2 · recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00732563 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 18 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00732563.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing